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1. Background to this report 
As part of the response to new psychoactive substances within the European Union (EU), the 
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk assessment 
and control of new psychoactive substances (hereafter 'the Council Decision') established a 
mechanism for the rapid exchange of information on substances that may pose public health and 
social threats, including the involvement of organised crime. This provides a legal basis for the 
institutions of the EU and the Member States to monitor all new narcotic and psychotropic 
substances that appear on the European drug scene. Where necessary, the Council Decision also 
provides for an assessment of the risks associated with these new substances, so that control 
measures deriving from Member States' obligations to the United Nations drug control 
conventions (1) can also be applied to new psychoactive substances. 
Under Article 4 of the Council Decision, the EMCDDA and Europol, in close collaboration with their 
respective expert networks, the Reitox National Focal Points and Europol National Units, are 
assigned a central role in detecting, notifying and monitoring new psychoactive substances. The 
information exchange element of the Council Decision has been implemented by the EMCDDA 
and Europol as the European Union Early Warning System on New Psychoactive Substances 
(hereafter ‘Early Warning System'). In addition, where necessary, and in cooperation with the 
European Medicines Agency (EMA), the EMCDDA and Europol may collect, analyse and present 
information on a new psychoactive substance in the form of a Joint Report (Article 5). This report 
provides evidence to the Council of the European Union and the European Commission on the 
need to request a risk assessment on a new psychoactive substance. Such a risk assessment 
examines the health and social risks posed by a new substance including: the use of, manufacture 
of, and, traffic in, a new psychoactive substance; the involvement of organised crime; and, the 
possible consequences of control measures. In order to conduct the risk assessment, the 
EMCDDA convenes a special meeting under the auspices of its Scientific Committee, extended 
with additional experts as necessary (Article 6). 
To ensure transparency in the implementation of the Council Decision, Article 10 stipulates that:  
'The EMCDDA and Europol shall report annually to the European Parliament, the Council and the 
Commission on the implementation of this Decision. The report will take into account all aspects 
required for an assessment of the efficacy and achievements of the system created by this 
Decision. The report shall, in particular, include experience relating to coordination between the 
system set out in this Decision and the Pharmacovigilance system'. 
(1) The 1961 United Nations Single Convention on Narcotic Drugs and the 1971 United Nations Convention on Psychotropic 
Substances. 
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 In compliance with Article 10, the EMCDDA and Europol herewith present the eighth such annual 
report which covers the period 1 January to 31 December 2013. The report outlines the results of 
the implementation, describes key issues arising from accumulated experiences, and also serves 
as a monitoring tool. In order to facilitate the reading of the report, the reader is referred to the full 
text of the Council Decision (2). 
The report is written as a standalone document with annexes kept to a minimum. Annex provides 
the list of new psychoactive substances notified for the first time in 2013. This includes the 
systematic chemical name, the reporting country, and date of notification for each substance. 
Further information on these substances is available from the EMCDDA and Europol.  
2. New psychoactive substances in 2013 
Since 1997, the EMCDDA and Europol have played a central role in the response to new 
psychoactive substances. Together, the two agencies, supported by their networks and other 
partners, have operated the world's only regional early warning system on new psychoactive 
substances; a system that has underpinned the ability to identify and respond to new psychoactive 
substances that pose social and public health harms within the EU. 
During 2013, 81 new psychoactive substances were reported for the first time within the EU 
(section 4.1). This compares to 74 in 2012 (3), 49 in 2011 and 41 in 2010. 
It should come as little surprise to most people that the majority of new psychoactive substances 
are intended as 'legal' replacements to controlled drugs. 2013 provided further evidence that 
entrepreneurs and increasingly organised crime groups (OCGs) are expanding on the types of 
substances they plan to offer as 'legal' alternatives. Of particular concern to the EMCDDA and 
Europol in this respect are the new synthetic opioids — such as AH-7921, MT-45, carfentanil and 
ocfentanil — reported in the past two years.  
Until about a decade ago, most new psychoactive substances that emerged were typically sold on 
the drug illicit market. Sometimes this was as drugs in their own right or as a new type of 'ecstasy', 
but often they were sold surreptitiously as amphetamine and MDMA. Only a handful was reported 
each year. Usually these were stimulant-type or hallucinogenic drugs produced in Europe or the 
United States either in small amounts in amateur laboratories or on a commercial scale in 
clandestine laboratories by organised crime groups. Sometimes new substances also emerged 
from the diversion of medicines. Importantly, this continues to be the case, with some of these 
substances simply acting as temporary substitutes  for established controlled drugs that are in 
(2) Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoac-
tive substances, OJ L 127, 20.5.2005, p. 32. 
(3) The 2012 annual report listed 73 substances as notified through the Early Warning System in 2012; this figure should have 
been 74. The synthetic cannabinoid JWH-302 (1-pentyl-3-(3-methoxyphenylacetyl)indole), was identified by Germany in Au-
gust 2012 but was not included in the 2012 annual report. 
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 short supply, such as MDMA; while others such as 4-methylamphetamine appear to be produced 
by accident arising from the use of uncontrolled precursors in the production of amphetamine. 
Only a few years ago the issue of new psychoactive substances was regarded as having limited 
significance to drug policy. In the past few years, however, there have been phenomenal changes 
in this market. Today the question of how to respond to the challenges posed by the emergence of 
new drugs has become a major concern within the EU and at the international level. 
The sale of new psychoactive substances through an open market took off in mid-2000s with the 
stimulants 1-benzylpiperazine (BZP, a piperazine derivative) and methylone, followed by 
mephedrone (cathinone derivatives). This marked the start of the modern ‘legal highs’ and the 
‘research chemicals’ market. Many of the new substances that are destined for these markets are 
produced in bulk outside of the EU (e.g. China and India) and imported into Member States, where 
they are processed, packaged and sold. Europol has received reports that such operations occur 
in a number of Member States. The marketing and distribution of these drugs has reached a new 
level of sophistication. This includes through the internet (with next day delivery to consumers), 
bricks and mortar ‘head shops’ in towns and cities, as well as by street level drug dealers. 
Globalisation and the new opportunities provided by developments in information technology have 
transformed many aspects of the new psychoactive substance market. A key player here is the 
Internet. Commerce and communication are no longer constrained by physical or geographical 
boundaries. This has also meant that the back catalogue of chemical substances developed by the 
pharmaceutical and medical research industries, and, whose psychoactive properties may make 
them attractive to consumers, is easily accessible to those wishing to identify such substances. 
Manufacturers in the chemical industries in China and India are able to synthesise the substances 
in bulk amounts. New trends also diffuse more rapidly, and a market-place for psychoactive 
substances has been created that exists, to a large extent, outside the established regulatory 
frameworks.  
As noted, 81 new psychoactive substances were reported for the first time within the EU during 
2013. Twenty-nine of these substances were synthetic cannabinoids (4). This brings the total 
number of synthetic cannabinoids reported since December 2008 to 104, making them the largest 
group of substances monitored by the Early Warning System; the large number clearly illustrating 
the continuing attempts by manufacturers to produce new substances in order to circumvent drug 
control measures. Also reported in 2013 were: 14 phenethylamines, 7 synthetic cathinones, 7 
arylalkylamines, 5 opioids, 2 benzodiazepines, a tryptamine, an aminoindane, an 
arylcyclohexylamine, a piperidines/pyrrolinde, a piperazine, and 12 substances that do not conform 
to the previous groups. 
(4) The term 'synthetic cannabinoids' is used here to include: synthetic cannabinoid receptor agonists (such as JWH-018 which is 
a CB1 and CB2 receptor agonist); allosteric modulators (such as Org 27569) that change the structure of the cannabinoid 
receptors leading to altered activity when a ligand binds to the receptors; and, substances that act as inhibitors of the fatty-
acid amide hydrolase (FAAH), which catalyses the intracellular hydrolysis of the endocannabinoid anandamide (such as 
URB597).   
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 Nine of the new substances reported in 2013 are used as the active pharmaceutical ingredients in 
medicines. The monitoring of such substances under the Council Decision can provide essential 
early warning on the emerging misuse and abuse of medicines authorised within the EU and also 
in third countries (5). An example of this in 2013 was the report from Italy that tropicamide, which is 
used in medicine to dilate the pupils, was being injected by opioid users. A review of the available 
information suggests that the injection of tropicamide has been reported in some eastern European 
countries. It appears to be used to self-treat opioid withdrawal symptoms and for its euphorigenic 
and hallucinogenic effects. 
A substantial part of the market in new psychoactive substances is those that are sold on the open 
market in head shops and online shops as 'legal highs' and 'research chemicals'. In 2013 the 
EMCDDA's monitoring of the Internet (6) identified 651 online shops selling these types of products 
to consumers in the EU (section 3.1.3). Europol has also gathered information from Member 
States on investigations regarding the online distribution of new substances in order to better 
understand how this market operates and the threats posed it. 
Adding to the complexity of this online market is the sale of new substances as 'food supplements'. 
This includes the plant kava kava and the medicine phenibut. These 'supplements' are of particular 
concern because the retailers and products are typically not covered by existing drug monitoring 
systems, effectively creating a blind spot in our understanding of the market. Some of these 
products are widely available on popular e-commerce sites, online health food shops, as well as in 
fitness equipment shops. In some cases these 'supplements' are marketed as 'natural' exploiting 
the general belief that they are safe and healthy options for consumers. One product that that was 
sold as a sport supplement and analysed in 2013 was found to contain a derivative of 
methamphetamine (substance 17, Annex). This product has been sold in a number of countries 
including Sweden, the United Kingdom, and the United States.  
2013 was also the year that sales of controlled drugs on the 'hidden' deep web, such as the now 
defunct Silk Road, really came to the public's attention. Less well known is that new psychoactive 
substances are also sold on the deep web, and work is required to better understand the 
importance to the EU drug market of such distribution networks, including sales to consumers. 
Of serious concern is that illicit production within the EU has been reported to Europol in 2013. 
Hungary, Poland and Slovakia have all reported the dismantling of illicit facilities where synthesis, 
processing and/or tableting of new psychoactive substances was taking place. These reports 
demonstrate that the processing of new substances within EU is not limited to mixing and 
packaging, but that organised crime groups have invested resources in illicit production facilities. 
(5) The terms ‘misuse' and ‘abuse’ are used in their regulatory sense within the medicine regulatory system. See: 
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/05/WC500143294.pdf  
(6) Monitoring was limited to retailers on the surface web selling direct to consumers.  
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 The number and type of new psychoactive substances reported each year is critical to 
understanding the development and growth of the market. These numbers, however, fail to convey 
the enormous amount of work undertaken by the Early Warning System Network at national and 
EU-level. For the EMCDDA and Europol, each report of a new substance requires that the 
information and analytical data is checked and assessed, that literature searches are run to see 
what is known about the substance, and that a technical profile is created on the European 
Database on New Drugs (EDND) at the EMCDDA. Simultaneously, the information is recorded and 
analysed by the Focal Point Synergy at Europol which is the hub for law enforcement data on 
synthetic drug crime including new psychoactive substances. From there, the substance is formally 
notified to the Early Warning System Network allowing laboratories, law enforcement, healthcare 
agencies, researchers, practitioners and policy makers to receive this critical data. This stage also 
marks the point at which the EMCDDA and Europol begin to monitor the new substance. Currently 
more than 380 new substances are monitored. The EDND, which is updated on a daily basis, 
plays a critical role in this monitoring by providing round-the-clock access on the latest information 
on new substances including, chemistry, pharmacology, toxicity, law enforcement seizures and 
epidemiology to the Early Warning System Network. 
In 2013, the EMCDDA and Europol also produced four Joint Reports on very different substances, 
both in terms of their chemistry, pharmacology, and individuals who use them: AH-7921, an opioid 
with similar effects to morphine; 25I-NBOMe, a potent hallucinogen; MDPV, a stimulant which in 
animal studies appears to be more potent and longer lasting than cocaine; and methoxetamine, a 
dissociative sold as a 'legal' and 'safer' alternative to ketamine (section 4.2). Reflecting the growing 
diversity of the market, 2013 marked the first time that formal action on an opioid (AH-7921) has 
been required at the EU-level. Also in 2013, a risk assessment was conducted by the EMCDDA's 
Scientific Committee on the stimulant 5-IT after 24 deaths associated with its use were reported 
over a short time period (section 4.3). 
While it is clear that many new substances will not gain a foothold as drugs in their own right and 
spread to broader groups of users, they are still capable of causing serious harm. The largely 
unknown pharmacology can pose serious risks to users. This is compounded by both the growing 
range of substances and the generally high availability. These problems are especially apparent 
when they are sold as 'legal highs' with no information provided to the user of the actual 
substance(s) present, and as a result of an increasing number finding their way to the black market 
where they are sold as ecstasy, cocaine, ketamine, heroin or LSD to unsuspecting users. In 
addition, while much focus has been given on the use of new substances by recreational users, 
they are also being used by problem drug users, including those who inject. This situation is 
presenting challenges for service providers, including low threshold services such as needle and 
syringe programmes that often have limited experience of these drugs and their effects. Little is 
also known about the treatment requirements of users of new psychoactive substances, which in 
part may reflect the fact that many have emerged only recently. 
Estimating the prevalence of use of new psychoactive substances continues to present challenges, 
especially through general population surveys. In some cases, such as with the synthetic 
cannabinoids, there is a clear discordance between the large number of multi-kilogram seizures 
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 reported to the Early Warning System and the levels of use reported in surveys. During 2013, the 
EMCDDA continued to work with its partners on ways to strengthen epidemiological methods and 
indicators related to the use of new substances. This includes exploring the development of 
indicators based on waste water analysis. 
Reports of serious adverse events from the Early Warning System Network — such as non-fatal 
intoxications that require hospital treatment and deaths — provide signals of emerging harms. 
Reflecting the growing number of such reports, in 2013 the EMCDDA began to develop a 
framework to strengthen the toxicovigilance component of the Early Warning System. This system 
will facilitate the identification and reporting of serious events as well as optimise the reported data 
in order to best analyse these signals. Ultimately this should allow the Member States and the EU 
to respond earlier to emerging harms. While there is a still long way to go in its full development, 
the EMCDDA has already begun to improve the quality of data that is reported by the Early 
Warning System Network related to serious adverse events. In addition, as a component of this 
system, the EMCDDA is developing a framework that allows it to more systematically monitor the 
media to pick up on these signals as early as possible and from a broader number of sources, 
including from countries outside of Europe. In fact the EMCDDA monitors the scientific and 
medical literature on a daily basis for reports of serious adverse events as well as data from 
nonclinical studies that help explain the cause of these events. These data are analysed and 
prioritised and are then fed into the broader monitoring process. 
In 2013, the EMCDDA issued 16 public health alerts and advisories to the Early Warning System 
Network (section 4.4). Many of these concerned serious adverse events, particularly deaths, 
and/or hazards that had the potential to cause serious harm. Notably alerts were issued on three 
potent new opioids – AH-7921, carfentanil, ocfentanil — that are appear to have only been sold on 
the drug market for the past two years or so. The EMCDDA and Europol are highly concerned 
about the number and type of new synthetic opioids reported to the Early Warning System in the 
past two years. Five of these opioids are fentanyls, a family of drugs that have already caused 
hundreds of deaths in Europe and the United States since they first appeared as 'designer drugs' 
sold as 'synthetic heroin' or 'China white' in California in the late 1970s. Adding to this concern is 
that some of the new opioids have already been sold as replacements to heroin. This includes a 
seizure made in Lithuania containing carfentanil (substance 6, Annex) which is usually used to 
tranquillise large animals such as elephants, and a seizure of ocfentanil in the Netherlands 
(substance 62, Annex). 
In September, Europol initiated the collection of available information on the new substance 4,4′-
DMAR, after eight deaths were reported by Hungarian police to be associated with the substance. 
4,4′-DMAR is a derivative of the designer drug 'U4Euh' (4-methylaminorex) and the weight-loss 
medicine aminorex which was withdrawn after it caused an epidemic of pulmonary hypertension. 
As a result of the information provided by Hungary, Europol and the EMCDDA issued alerts to their 
respective partners within the Early Warning System Network (see ‘Update from 2014’, below). 
The effective exchange of information on new psychoactive substances underpins an effective 
response. During 2013 the EMCDDA and Europol provided formal training in order to strengthen 
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 early warning both at the national and EU-level. Reflecting the globalised nature of this 
phenomenon, international cooperation with third countries was strengthened further. This included 
the bilateral exchange of technical information with law enforcement and healthcare agencies from 
the United States, Japan, Australia, among others. The importance of these global partnerships 
continues to be highlighted by the exchange of information on serious adverse events. In 2013, 
alerts were issued related to outbreaks of serious adverse events associated with synthetic 
cannabinoids that were reported to the EMCDDA by law enforcement agencies in the United 
States. While during the Third International Forum on New Drugs, experts from around the world 
came together to exchange experiences, identify information gaps and research needs, as well as 
anticipate future developments and challenges. 
Update from 2014 
There appears to be no slowdown in the growth of the phenomenon. As of May, 37 new 
psychoactive substances have been reported to the Early Warning System. 
The eight deaths associated with 4,4′-DMAR reported by Hungary in 2013 were joined by reports 
of a further 18 deaths from the United Kingdom in February 2014, leading the EMCDDA and 
Europol to launch a Joint Report on 4,4′-DMAR in the same month. The substance continues to be 
intensively monitored by the Early Warning System. Twenty seven deaths associated with the 
substance have now been reported; a particular concern in this respect is that more than 260 kg of 
4,4′-DMAR has been seized in the Netherlands, and that in some countries it has been sold as 
ecstasy on the illicit drug market. The availability of 4,4′-DMAR may also mark an astonishing 
development in the 'research chemical' market after the suggestion that the distributors have 
conducted testing of the substance in animals, with the data from these tests being used as part of 
the marketing. If this is correct then distributors may be attempting to consolidate a 'legal' market in 
new substances. 
Also in 2014, 21 deaths and thirteen non-fatal intoxications associated with the new opioid MT-45 
have been reported. Of particular concern in this respect is that this substance appears to have 
only been sold on the drug market for the past six months or so. On the basis of these reports a 
Joint Report on MT-45 was launched in April by the EMCDDA and Europol (substance 74, Annex). 
The substance continues to be intensively monitored by the Early Warning System. 
The growing involvement of organised crime groups apparently drawn by the large profits from this 
market is of serious concern to Europol. Analysis of intelligence reports provided by the Member 
States indicates that in the near future criminal groups based within the EU will expand their 
involvement in the trade, manufacture, trafficking and distribution of new psychoactive substances. 
There is little doubt that enhanced monitoring systems within some national early warning systems 
are playing a key role in the early identification of serious adverse events and other harms by the 
Early Warning System. Such systems will require adequate resources if they are to continue to 
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 supply this essential data and scale-up to provide enhanced coverage. Resources will also be 
required in order to replicate these enhancements in other settings and regions. 
For the past few years the EDND has begun to feel the strain as a result of both the huge increase 
in the amount and types of data now being reported. Resources are urgently required in order to 
ensure it can meet the needs of the EU in both in the near future and longer-term. 
3. Implementation arrangements and cooperation with the European Union 
Pharmacovigilance system 
3.1 Specific implementation arrangements 
3.1.1 Assistance to national early warning systems  
In 2013, the EMCDDA and Europol continued to provide support to the national early warning 
systems within the National Focal Points and Europol National Units in order to assist them in the 
identification of new substances. Assistance related to new psychoactive substances from the 
Member States as well as Institutions and agencies of the EU was also provided.  
The analytical data available to the Early Warning System Network continued to be expanded 
during 2013. In addition, data and information is now routinely provided on an informal basis by 
international partners, including Australia, the United States and Japan. This is an important aspect 
of the exchange of information and emphasises the global nature of the phenomenon.  
The EMCDDA also collects national risk assessments on new psychoactive substances which are 
made available on the EDND in order to help identify emerging harms as well as inform policy 
responses in the Member States. Similarly, legislative developments related to new substances 
reported by the Member States are also recorded and tracked. 
Training was also provided to some of the Member States (section 3.1.4). 
3.1.2 Annual meeting of the Early Warning System Network  
The 13th annual meeting of the Reitox Early Warning System Network took place on 27 June 2013. 
The meeting was organised in conjunction with the second Europol law-enforcement meeting on 
new psychoactive substances and the Third International Multidisciplinary Forum on New Drugs. 
Over 70 representatives from the Early Warning System Network and Europol networks in the 28 
Member States, Turkey and Norway attended the forum as well as delegates from 10 third 
countries. Experts from a wide range of disciplines also attended. This included both from 
academic and operational backgrounds, such as epidemiology, forensic science, healthcare, law-
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 enforcement, criminology and policy. The forum aimed to identify information gaps and research 
needs, anticipate future developments and challenges and explore the role that can be played by 
law enforcement. Topics discussed included: 
• historical context, public health perspective, motivations of users, the role of law 
enforcement, challenges for drug policy; 
• national, regional and global perspectives on new drugs, including presentations on 
significant developments and initiatives taking place around the globe; 
• how emerging harms can be detected, monitored and understood by the work of forensic 
science, toxicology and healthcare disciplines; 
• the role of law enforcement in the response to new drugs, including the difficulties faced by 
the growing interplay between new drugs and illicit drug markets; 
• good practice and novel approaches, including what can be learned from the users of new 
drugs; and, 
• the response to new drugs, which included a discussion of the recent policy developments 
in New Zealand. 
3.1.3 Monitoring of the online availability of new psychoactive substances  
In 2013 the EMCDDA, in partnership with some of the National Focal Points, undertook an Internet 
monitoring exercise in 18 languages of the EU, Norwegian and Russian. The aim of the exercise 
was to provide a snapshot of the online sale of new psychoactive substances to consumers within 
the EU. The snapshot identified 651 shops which typically sold new substances as 'legal high' 
products or 'research chemicals'; in some cases products were also identified that were sold as 
'food supplements'. In comparison, the previous snapshot exercise in January 2012 identified 693 
shops, while the snapshots conducted in January 2011 and 2010, identified 314 and 170 shops, 
respectively (7,8). 
A targeted Internet snapshot in English was also conducted in 2013 to provide data to support the 
risk assessment of 5-IT (section 4.3.1). 
(7)  EMCDDA (2011), Online sales of new psychoactive substances/'legal highs': summary of results from the 2011 multilingual 
snapshots, EMCDDA, Lisbon. Available at: http://www.emcdda.europa.eu/publications/scientific-studies/2011/snapshot 
(8) It is important to note that the data between different snapshots may not be directly comparable, due to changes in the meth-
odology which have increased the quality and coverage of these surveys over time; in addition, changes in technology, such 
as the algorithms used by search engine, can also affect the comparability between different snapshots.  
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 3.1.4 Supporting activities 
During 2013 the EMCDDA and Europol continued to be prominently involved in organising events 
and participating in activities that are designed to develop the Early Warning System Network and 
provide support to others working in the field of new psychoactive substances. These events and 
activities provide a platform to improve collaboration among partners and promote best practice in 
order to strengthen early warning activities. Significant activities carried out in 2013 are provided 
below. 
In April a Reitox Academy training event examining contemporary approaches to drug monitoring 
was organised in Prague, Czech Republic for Western Balkan countries and Turkey. The 
EMCDDA provided a keynote lecture on  new psychoactive substances, including the critical role 
that Internet plays in this phenomenon. The event also incorporated a training session on 
monitoring the supply of new psychoactive substances on the Internet. A pilot internet snapshot in 
Balkan languages (Montenegrin, Macedonian, Bosnian, Serbian, Albanian, Croatian and Turkish) 
was implemented during the training. 
In May training was provided at the 'Workshop on New Psychoactive Substances, the Health 
Dimension', in Zagreb, Croatia, funded under the European Commission's TAIEX instrument and 
organised by the Croatian Office for Combatting Drug Abuse. Also in May the annual meeting of 
the Drugs Working Group of the European Network of Forensic Science Institutes (ENFSI) was 
held in Dubrovnik, Croatia, in which the EMCDDA actively participated as an associate member of 
the network. 
In June the EMCDDA assisted Europol by providing a training input at the Cepol–Europol 
International Illicit Synthetic Drug Laboratory Dismantling Course, held at the national police 
training centre in Legionowo, Poland. 
In September the Second International Conference on Novel Psychoactive Substances took place 
in Swansea, United Kingdom. As well as co-organising the event, the EMCDDA participated with 
two keynote speeches and chaired or co-chaired the plenary and parallel sessions of the 
Conference. 
In October a meeting of forensic drug experts representing different institutions took place at the 
EMCDDA in Lisbon, Portugal. During this meeting the participants explored the possibilities to 
improve processes, particularly in relation to the interaction of the forensic community with the 
Early Warning System. 
In November the EMCDDA attended the Spanish national early warning system meeting in Madrid 
to provide a European overview and best practice example to strengthen the national network.  
 
11072/14   JV/fm 11 
 DG D 2C  EN 
 
 The EMCDDA also organised or participated in a number of meetings with dedicated sessions on 
new psychoactive substances, reflecting the relevance of this area for traditional illicit drug areas 
and established key epidemiological indicators. This included meetings covering general 
population surveys, drug-related deaths, and problem drug use. In May, the EMCDDA organised 
the first international multidisciplinary conference on detecting illicit drugs in wastewater 'Testing 
the waters', with a dedicated session on the potential of sewage analysis for identifying and 
monitoring population-level trends of new drugs in wastewater. In October, the EMCDDA co-
organised with COPOLAD a thematic twinning training on analysis, interpretation and 
dissemination of drug-related data to facilitate decision making. 
3.2 Cooperation with the EMA and the Pharmacovigilance system 
During 2013, the EMA and EMCDDA continued to regularly exchange information on new 
psychoactive substances according to their respective obligations under the Council Decision and 
EU pharmacovigilance legislation as well as the working arrangement between the two agencies 
(9). This included ad hoc reports relating to the misuse and abuse of medicinal products, or the 
active pharmaceutical ingredients used therein, that had been notified as new psychoactive 
substances, in order to support the Pharmacovigilance system. At the request of the EMCDDA, the 
EMA  provided pharmacovigilance data on phenibut (notified in 2010) and information on 
authorised medicinal products containing tropicamide as well as pharmacovigilance data on these 
products related to their misuse, including by injection (substance 25, Annex 2). Formal 
consultations and exchange of information took place in order to prepare the Joint Reports on 25I-
NBOMe, AH-7921, MDPV and methoxetamine (section 4.2). In addition, at the request of the EMA, 
the EMCDDA undertook a data collection exercise with the Early Warning System Network in order 
to provide information on the misuse and abuse of pregabalin (notified in 2009). 
4. Activities  
4.1 New psychoactive substances notified in 2013 
Eighty-one new psychoactive substances were notified for the first time in 2013 (Table 1 and 
Annex). This continues the year on year increase in the number of new substances that have been 
notified since 2008 (Figure 1).  
Technical profiles were created on the European Database on New Drugs (EDND) for each of the 
notified substances as well as five substances of interest. During the course of 2013, 444 reporting 
forms were submitted by the Early Warning System Network which were processed, analysed and 
added to the EDND; while 300 technical profiles on the EDND were updated with the information 
from these forms as well as from other sources including regular searches of the scientific and 
medical literature that is conducted by the EMCDDA and additional law enforcement information 
provided by Europol. 
(9) http://www.emcdda.europa.eu/attachements.cfm/att_185319_EN_EMA-EMCDDA-2012workingarrangement.pdf  
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 Technical assistance, advice and feedback were provided to the Member States on a daily basis. 
Sixteen public health alerts or advisories were issued to the Early Warning System Network 
(section 4.4). Additional data collection and analysis took place on an ad hoc basis, including for 
the Joint Reports on 25I-NBOMe, AH-7921, MDPV and methoxetamine (section 4.2).  
As part of a process that began in 2012, the EMCDDA has been reviewing its classification system 
for new psychoactive substances. In the main it is possible to group some substances by their 
chemical family or in the case of the synthetic cannabinoids by their mode of action. The former 
has long been the case with the phenethylamines, tryptamines, piperazines and cathinones. To 
take account of the increasing diversity of substances that have been notified in recent years, six 
new categories have been introduced during 2013: arylcyclohexylamines, aminoindanes, 
arylalkylamines, benzodiazepines, piperidines and pyrrolidines. The category of ‘opioids' has also 
been introduced based on mode of action; this group contains eleven substances, ten of which 
have been notified since 2012. A category has also been created for plants and extracts of plants; 
no substances were reported in this group in 2013. Substances that do not conform to the groups 
described above were grouped separately, in an 'others' category. 
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Substance category 2013 
Synthetic cannabinoids 29 
Phenethylamines 14 
Other substances 12 
Arylalkylamines 7 
Cathinones 7 
Opioids 5 
Benzodiazepines 2 
Tryptamines 1 
Aminoindanes 1 
Arylcyclohexylamines 1 
Piperazines 1 
Piperidines & pyrrolidines 1 
Plants & extracts 0 
Table 1. Number of new psychoactive substances notified for the first time in 2013 by category.  
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 Figure 1. Number of new psychoactive substances notified for the first time to the Early Warning System 
since May 2005 (by year) (10) 
4.2 EMCDDA-Europol Joint Reports 
In accordance with Article 5 of the Council Decision, after a review of the available information on 
the new psychoactive substances 25I-NBOMe, AH-7921, MDPV and methoxetamine, a formal 
procedure for the collection of information on these four new substances was launched by the 
EMCDDA and Europol on 7 October 2013. The Joint Reports were submitted to the Council, the 
Commission and the EMA on the 16 December 2013. A summary of the key findings for each of 
the four Joint Reports are provided below. 
On the basis of the information provided therein, on the 29 January 2014 the Council requested 
that formal risk assessments be conducted on the substances. In accordance with Article 6 of the 
Council Decision, the risk assessments were conducted by the extended Scientific Committee of 
the EMCDDA on 1 and 2 April 2014. A Risk Assessment Report for each substance was submitted 
to the Council and the Commission on the 22 April 2014 (11). 
4.2.2 Joint Report on 25I-NBOMe 
25I-NBOMe is a substituted phenethylamine. It is a potent full agonist of the serotonin 5-HT2A 
receptor and appears to have hallucinogenic effects. It has been available on the European Union 
drug market since at least May 2012 and has been detected in 23 Member States and Norway. 
Severe toxicity associated with its use has been reported in four Member States and one death 
associated with 25I-NBOMe has been analytically confirmed. Seven countries have reported that it 
has been sold as LSD or as a 'legal' alternative to LSD. On this basis the potential impact from the 
further spread of 25I-NBOMe (and related 'NBOMe' compounds) on public health is a key concern 
(12). 
4.2.3 Joint Report on AH-7921 
AH-7921 is a synthetic opioid. It has been available in the EU since at least July 2012 and has 
been detected in seven Member States and Norway. In most cases it has been seized in small 
quantities as a powder. Over a short period of time it has been associated with fifteen deaths and 
six non-fatal intoxications in three countries. The similarity of AH-7921 to morphine in terms of 
(10) As noted the 2012 annual report listed 73 substances as notified through the Early Warning System in 2012; this figure should 
have been 74. The synthetic cannabinoid JWH-302 (1-pentyl-3-(3-methoxyphenylacetyl)indole), was identified by Germany in 
August 2012 but was not included in the 2012 annual report.  
(11) The Risk Assessment Reports are available at:  http://www.emcdda.europa.eu/publications/risk-assessments 
(12) EMCDDA and Europol (2014), EMCDDA–Europol Joint Report on a new psychoactive substance: 25I-NBOMe (4-iodo-2,5-
dimethoxy-N-(2-methoxybenzyl)phenethylamine), Lisbon, January 2014. Available at: 
http://www.emcdda.europa.eu/publications/joint-report/25I-NBOMe 
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 pharmacology is a key concern. This may play an important role in the further spread of AH-7921 
by opioid users, including the injecting population (13). 
4.2.4 Joint Report on MDPV 
MDPV is a synthetic cathinone derivative, which is closely related to pyrovalerone. MDPV has 
been present in the EU drug market since at least November 2008 and has been detected in 99 
deaths and up to 107 non-fatal intoxications, particularly in Finland and the United Kingdom. There 
are some indications that it has been sold as a 'legal' or synthetic version of cocaine and it has 
also been found in tablets resembling 'ecstasy'. Large seizures have been made at borders and 
police operations have targeted its supply. Powder seizures have been reported including multi-
kilogram quantities. Most, but not all the Member States have control measures at national level 
that cover MDPV, however, it continues to be available and this is concerning (14). 
4.2.5 Joint Report on methoxetamine 
Methoxetamine is an arylcyclohexylamine, closely related in many respects to ketamine. It has 
been available on the EU drug market since at least September 2010 and has been detected in 22 
Member States, Turkey and Norway. Multi-kilogram quantities of the substance in powder form 
have been seized. Twenty deaths and 110 non-fatal intoxications associated with the substance 
have been reported. As methoxetamine is marketed as a legal and 'bladder-friendly' alternative to 
ketamine and at the same time being sold directly on the illicit drug market as ketamine, a key 
concern is that these may play a role in the further spread of the substance (15). 
4.3 Risk assessments  
4.3.1 Risk assessment of 5-IT 
During 2012, a Joint Report on 5-IT (5-(2-aminopropyl)indole) was prepared by the EMCDDA and 
Europol and submitted to the Council, Commission and EMA on 12 December 2012 (16). This led 
to a request from the Council for a formal risk assessment on January 2013. The risk assessment 
was conducted, in accordance with Article 6 of the Council Decision, by the extended Scientific 
(13)  EMCDDA and Europol (2014), EMCDDA–Europol Joint Report on a new psychoactive substance: AH-7921 (3,4-dichloro-N-
[[1-(dimethylamino)cyclohexyl]methyl]benzamide), Lisbon, January 2014. Available at: 
http://www.emcdda.europa.eu/publications/joint-report/AH-7921 
(14)  EMCDDA and Europol (2014), EMCDDA–Europol Joint Report on a new psychoactive substance: MDPV (3,4-
methylenedioxypyrovalerone), Lisbon, January 2014. Available at: http://www.emcdda.europa.eu/publications/joint-
report/MDPV 
(15) EMCDDA and Europol (2014), EMCDDA–Europol Joint Report on a new psychoactive substance: methoxetamine (2-(3-
methoxyphenyl)-2-(ethylamino)cyclohexanone), Lisbon, January 2014. Available at: 
http://www.emcdda.europa.eu/publications/joint-report/methoxetamine 
(16) EMCDDA and Europol (2012), EMCDDA–Europol Joint Report on a new psychoactive substance, 5-(2-aminopropyl)indole, 
EMCDDA, Lisbon. Available at: http://www.emcdda.europa.eu/publications/joint-reports/5-IT 
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 Committee of the EMCDDA on 16 April 2013, which included a representative from Europol, the 
EMA and Commission. Discussions during the risk assessment focused on the 24 deaths and 20 
non-fatal intoxications associated with 5-IT that had been reported. The deaths occurred in four 
Member States over a period of five months in 2012, raising concern that if 5-IT were to become 
more widely available and used, the implications for public health could be significant. Full details 
are provided in the EMCDDA report on the risk assessment (17). 
On 7 October 2013 the Council adopted a decision to subject 5-IT to control measures across the 
EU (18).  
4.4 Public health alerts and advisories 
One of the activities of the Early Warning System that provides added value to the Member States 
is public health alerts and advisories. Usually these concern deaths or other serious adverse 
events associated with new psychoactive substances; they can also include hazards that have the 
potential to cause serious harm (19). In addition, information is also exchanged on emerging trends 
in new uses of psychoactive substances that are controlled under the United Nations drug 
conventions and that may pose a potential risk to public health. Alerts and advisories may also 
provide information on possible public health related measures in accordance with the mandate 
and procedures of the EMCDDA. 
Sixteen public health alerts and advisories were issued to the Early Warning System Network 
during 2013. A selection is provided below (20).  
Carfentanil 
In February an alert was issued after the Latvian National Focal Point reported that the highly 
potent opioid and fentanyl derivative had been identified in a seizure of powder made by Latvian 
Police. The information also noted that this substance had been associated with a number of 
unconfirmed deaths in the country. 
(17)  EMCDDA (2014), Report on the risk assessment of 5-(2-aminopropyl)indole in the framework of the Council Decision on new 
psychoactive substances, Publications Office of the European Union, Luxembourg. Available at: 
http://www.emcdda.europa.eu/publications/risk-assessment/5-IT 
(18) Council Decision of 7 October 2013 on subjecting 5-(2-aminopropyl)indole to control measures (2013/496/EU), OJ L 272, 
12.10.2013, pp. 44-45. 
(19)  Alerts and advisories issued by the Early Warning System are not legally binding and Member States are not obliged to act 
upon them. 
(20)  Note that the detection of new psychoactive substances in post-mortem biological samples does not necessarily imply a 
causal role in the death. 
 
11072/14   JV/fm 17 
 DG D 2C  EN 
 
                                                 
 AH-7921 
In February an alert was issued after the Norwegian National Focal Point reported that the opioid 
AH-7921 had been identified in a seizure of powder as well as in contents of a used syringe that 
was seized in connection with a death that was believed to be linked to the substance. Other alerts 
were issued during 2013 related to AH-7921 after reports of deaths associated with the substance 
were received from Sweden and Norway. 
25I-NBOMe 
In February an alert was issued after the United Kingdom National Focal Point reported 7 serious 
non-fatal intoxications associated with the use of the potent hallucinogen 25I-NBOMe that occurred 
in January 2013. 
4,4-Dimethylaminorex (4,4′-DMAR) 
In October an alert was issued after the Hungarian National Focal Point reported 8 deaths 
associated with the 4,4′-DMAR, which is believed to be a stimulant-type substance. This alert 
facilitated work by the United Kingdom national early warning system in identifying 18 deaths 
associated with 4,4′-DMAR which were subsequently reported to the Early Warning System in 
February 2014. 
Ocfentanil 
In September an alert was issued after the Netherlands National Focal Point reported the 
identification of the opioid and fentanyl derivative ocfentanil in a seizure made by Dutch police 
which may have been intended to be sold on the drug market as 'synthetic heroin'. 
ADB-PINACA and 5F-ADBICA 
In September an advisory was issued after information provided by law enforcement agencies in 
the United States, supplemented by information from the EMCDDA's monitoring of open source 
information, identified a series of non-fatal intoxications in the United States associated with ADB-
PINACA and 5F-ADBICA. These substances are known to be present on the EU drug market and 
have been reported by several Member States. 
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 5-EAPB 
In December an alert was issued after the Swedish National Focal Point reported a death 
associated with 5-EAPB, a substance which has a chemical structure very similar to the well-
known ecstasy drug MDMA. 
5. Conclusions 
2013 saw the sustained growth of the market in new psychoactive substances within the EU. The 
new psychoactive substances reported this year unequivocally demonstrate a growing diversity in 
the types of substances being sold as 'legal' alternatives to controlled drugs. Of particular concern 
from a public health perspective are the new synthetic opioids that have been identified on the 
drug market in the past two years, such as AH-7921, MT-45, carfentanil and ocfentanil.  These 
developments are compounded by the growing involvement of organised crime groups (OCGs) 
who appear to be drawn to the market by the potential large profits from this market.  Europol’s 
analysis of intelligence reports indicates that in the near future criminal groups based within the EU 
may expand their involvement in the trade, manufacture, trafficking and distribution of new 
psychoactive substances. 
Despite these challenges, the Early Warning System, as well as the EMCDDA–Europol Joint 
Reports and the risk assessment conducted by the EMCDDA extended Scientific Committee 
continue to demonstrate the added value and strength of the EU system by ensuring robust data-
driven analysis, assessment and response to the harms posed by new psychoactive substances. 
The EMCDDA and Europol have devoted substantial internal resources to ensure that the current  
information exchange system setup under Council Decision 2005/387/JHA, and  
operationalised as the Early Warning System, has been successfully implemented on a continuous 
basis. Through the support of its partners, including the EMA, the Early Warning System provides 
added value to the Member States by playing an essential role as a sentinel network that ensures 
that they have access to the most up-to-date information on new psychoactive substances both 
from across Europe and beyond. The Early Warning System Network continues to grow, as does 
the amount and quality of the information that it collects. This continued development is 
underpinned by the Reitox National Focal Points and the Europol National Units who need to be 
adequately supported. There is little doubt that enhanced national monitoring systems are playing 
a key role in the early identification of harms by the Early Warning System. Such systems will 
require adequate resources if they are to continue to supply this essential data and scale-up to 
provide enhanced coverage. Resources will also be required in order to replicate these 
enhancements in other settings and regions. In addition there is a critical need for a strengthened 
data collection mechanism so that the Early Warning System can both effectively cope with the 
recent significant growth in the data and ensure that it can be monitored. 
Monitoring new psychoactive substances is event-based. It is driven by the identification of new 
psychoactive substances in laboratory settings which are predominantly not research focused. 
These analytical and toxicological laboratories are the cornerstone of the Early Warning System. 
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 They may be located at law enforcement, private sector, (public) health, academic establishments, 
etc. This is routine work for these laboratories and they urgently require both the enhanced 
provision of analytical data through a strengthened European Database on New Drugs (EDND) 
(see below) and a cost-effective mechanism to share reference standards easily and rapidly within 
the EU.  
Given the growing role that organised crime groups (OCGs) are likely to play in the manufacture 
and supply of new psychoactive substances in the future it is essential that adequate resources 
and expertise are available to law enforcement agencies at both national and EU-level.   
The toxicovigilance component of the Early Warning System is the mechanism that allows the 
early detection of an emerging toxicological problem—and an initial assessment of the potential 
scale of the problem—related to a new substance both at national and EU-level. This allows both 
public health warnings to be issued to the Early Warning System Network, and for the substance to 
be placed under intensive monitoring. In some cases this may also lead to formal action through a 
Joint Report, and, where necessary a risk assessment. In order for the EMCDDA to meet the 
increased needs and demands arising from the phenomenon, both at national and EU level, the 
identification, reporting and monitoring of serious adverse events requires strengthening.   
For many years the European Database on New Drugs (EDND) has served the EU well by acting 
as a reference point on the available information on new psychoactive substances. However, 
adequate resources are not available to enable its development to keep pace with the amount and 
type of data arising from the increasing number of substances that are being identified and ensure 
effective monitoring. The EDND should be strengthened. A core part of this work will require the 
development of a new infrastructure that will allow secure electronic submission of data through 
standard web-based structured forms as well as facilitate the central analysis of data and 
production of reports. Alongside being able to provide real time information on a new drug (or a 
particular aspect of a new drug such as its detection in a particular ‘legal high’ product or reports of 
serious adverse events), the system should be able to provide an overview of the phenomenon as 
a whole to stakeholders. Resources are urgently required in order to ensure it can meet the needs 
of the EU in both in the near future and longer-term. 
By its very nature the risk assessment process is completed in a short time-frame. As a result 
limited data is available, and the process is principally focused on the data related to acute harm. It 
is important to recognise here that the data provided and collected through the Early Warning 
System will be essential to this process, particularly in relation to serious adverse events. In 
addition, targeted non-clinical studies that characterise the pharmacological and toxicological 
properties of the new psychoactive substances will be required for the risk assessment process in 
order to understand the data reported through the Early Warning System. In order to provide these 
data sufficient resources must be made available. 
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 It is hoped that the information and analysis provided by the EMCDDA and Europol in this report 
will provide greater insight in the growing complexity of the market in new psychoactive 
substances, and, as a result, the challenges that the Member States and the EU are likely to face 
in the near future. In addition, it is also hoped that the report can help inform the policy responses 
currently being discussed at EU-level. 
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 Annex. New psychoactive substances notified to the Early Warning System for the first time 
in 2013 under the terms of Council Decision 2005/387/JHA. 
1. 5-MAPB (1-(benzofuran-5-yl)-N-methylpropan-2-amine) – 3 January 2013, United Kingdom. 
2. 4-Fluorocathinone (2-amino-1-(4-fluorophenyl)propan-1-one) – 10 January 2013, Finland. 
3. JWH-methylcyclohexane-8quinolinol (Quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
carboxylate) – 29 January 2013, Spain. 
4. A-834,735 ([1-(tetrahydropyran-4-ylmethyl)indol-3-yl]-(2,2,3,3-
tetramethylcyclopropyl)methanone) - 29 January 2013, Poland. 
5. JWH-368 ([5-(3-fluorophenyl)-1-pentyl-pyrrol-3-yl]-(1-naphthyl)methanone) – 7 February 2013, 
Latvia. 
6. Carfentanil (methyl 1-(2-phenylethyl)-4-[phenyl(propionyl)amino]-4-piperidinecarboxylate) – 12 
February 2013, Latvia. 
7. EAM-2201 ((4-ethyl-1-naphthyl)-[1-(5-fluoropentyl)indol-3-yl]methanone) – 15 February 2013, 
Sweden 
8. Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one) – 7 
March 2013, Germany. 
9. 5F-PB22 (8-quinolyl 1-(5-fluoropentyl)indole-3-carboxylate) – 15 March 2013, Belgium. 
10. JWH-307 brominated derivative ((5-(2-bromophenyl)-1-pentyl-1H-pyrrol-3-yl)(naphthalen-1-
yl)methanone) – 4 April 2013, Germany. 
11. JWH-030 (naphthalen-1-yl(1-pentyl-1H-pyrrol-3-yl)methanone) – 4 April 2013, Germany. 
12. JWH-145 (naphthalen-1-yl(1-pentyl-5-phenyl-1H-pyrrol-3-yl)methanone) – 4 April 2013, 
Germany. 
13. UR-144 heptyl derivative ((1-heptyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone) 
– 17 April 2013, Sweden. 
14. 3,4-dichloromethylphenidate (methyl (2R)-2-(3,4-dichlorophenyl)-2-[(2R)-piperidin-2-yl]acetate) 
– 17 April 2013, Sweden. 
15. 25H-NBOMe (2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine) – 24 April 2013, 
Sweden. 
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 16. URB-597 ([3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate) – 24 April 2013, Poland. 
17. N-ethyl-1-phenylbutan-2-amine – 2 May 2013, Sweden. 
18. AB-PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) – 21 
May 2013, Sweden. 
19. α-PVT (2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)pentan-1-one) – 21 May 2013, Hungary. 
20. A-836,339 (N-[3-(2-methoxyethyl)-4,5-dimethyl-1,3-thiazol-2-ylidene]-2,2,3,3-
tetramethylcyclopropane-carboxamide) – 3 June 2013, Hungary. 
21. 4-methylbuphedrone, N-benzyl derivative (2-(benzylamino)-1-(4-methylphenyl)butan-1-one) – 5 
June 2013, Finland. 
22. 2-Me-DMT (N,N-dimethyl-2-(2-methyl-1H-indol-3-yl)ethanamine) – 5 June 2013, Finland. 
23. 4-MeO-α-PVP (1-(4-methoxyphenyl)-2-(pyrrolidin-1-yl)pentan-1-one) – 12 June 2013, Finland. 
24. NMP (1-methylpyrrolidin-2-one) – 13 June 2013, Italy. 
25. Tropicamide (N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide) – 2 July 2013, 
Italy . 
26. RH-34 (3-[2-(2-methoxybenzylamino)ethyl]-1H-quinazoline-2,4-dione) – 4 July 2013, France. 
27. 2-(2,3-dimethoxyphenyl)-N-(3,4,5-trimethoxybenzyl)ethanamine – 4 July 2013, France. 
28. JTE-907 (N-(benzo[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinolin-3-
carboxamide) – 4 July 2013, Germany. 
29. AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
carboxamide) – 4 July 2013, Belgium. 
30. 5F-AB-PINACA (N-(1-carbamoyl-2-methyl-propyl)-1-(5-fluoropentyl)indazole-3-carboxamide) – 
5 July 2013, Belgium. 
31. Mebroqualone (3-(2-bromophenyl)-2-methylquinazolin-4(3H)-one) – 5 July 2013, United 
Kingdom. 
32. Allylescaline (4-allyloxy-3,5-dimethoxy-phenethylamine) – 8 July 2013, Denmark. 
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 33. α-PEP (1-phenyl-2-(1-pyrrolidinyl)heptan-1-one) – 8 July 2013, Sweden. 
34. 5-EAPB (1-(1-benzofuran-5-yl)-N-ethylpropan-2-amine) – 11 July 2013, United Kingdom. 
35. Mephtetramine (2-((methylamino)methyl)-3,4-dihydronaphthalen-1(2H)-one) – 11 July 2013, 
United Kingdom. 
36. Escaline (3,5-dimethoxy-4-ethoxyphenethylamine) – 15 July 2013, Germany. 
37. βk-PBDB (1-(1,3-benzodioxol-5-yl)-2-(propylamino)butan-1-one) – 17 July 2013, Czech 
Republic. 
38. Proscaline (2-(3,5-dimethoxy-4-propoxyphenyl)ethanamine) – 7 August 2013, Netherlands. 
39. W-15 ((E)-4-chloro-N-(1-phenethylpiperidin-2-ylidene)benzenesulfonamide) – 12 August 2013, 
Spain. 
40. Nitracaine (3-(N,N-diethylamino)-2,2-dimethylpropyl-4-nitrobenzoate) – 13 August 2013, 
Sweden. 
41. Diclazepam (7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one) – 
26 August 2013, Germany. 
42. Methoxetamine brominated derivative (2-(2-bromo-5-methoxy-phenyl)-2-
(ethylamino)cyclohexanone) – 28 August 2013, Poland. 
43. 25iP-NBOMe (2-[2,5-dimethoxy-4-(propan-2-yl)phenyl]-N-(2-methoxybenzyl)ethanamine) – 6 
September 2013, Finland. 
44. 3C-P (1-(3,5-dimethoxy-4-propoxyphenyl)propan-2-amine) – 6 September 2013, Finland. 
45. 3C-E (1-(4-ethoxy-3,5-dimethoxyphenyl)propan-2-amine) – 6 September 2013, Finland 
46. 25I-NBMD (N-(1,3-benzodioxol-4-ylmethyl)-2-(4-iodo-2,5-dimethoxy-phenyl)ethanamine) – 6 
September 2013, Poland. 
47. 6-MAPB (1-(benzofuran-6-yl)-N-methylpropan-2-amine) – 10 September 2013, United 
Kingdom. 
48. LY2183240 (N,N-dimethyl-5-[(4-biphenyl)methyl]tetrazole-1-carboxamide) – 10 September 
2013, United Kingdom. 
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 49. Methoxypiperamide ((4-methoxyphenyl)(4-methylpiperazine-1-yl)methanone) – 11 September 
2013, United Kingdom.  
50. bk-MPA (2-(methylamino)-1-(thiophenyl-2-yl)propan-1-one) – 12 September 2013, Hungary 
51. AM-1248 azepane isomer ((adamant-1-yl)[1-(1-methylazepan-3-yl)-1H-indol-3-yl]methanone) – 
26 September 2013, Hungary. 
52. Methallylescaline (2-[3,5-dimethoxy-4-[(2-methyl-prop-2-en-1-yl)oxy]phenyl]ethanamine) – 11 
October 2013, Sweden. 
53. C30-NBOMe (2-(4-chloro-2,5-dimethoxy-phenyl)-N-[(3,4,5-
trimethoxyphenyl)methyl]ethanamine) – 11 October 2013, Sweden . 
54. ADBICA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide), 11 
October 2013, Sweden. 
55. Gabapentin (2-[1-(aminomethyl)cyclohexyl]acetic acid) – 15 October 2013, Belgium. 
56. Sibutramine (1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethyl-1-butanamine) – 15 October 
2013, United Kingdom. 
57. Venlafaxine (1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol) – 15 October 2013, 
Austria. 
58. 2-FMC (1-(2-fluorophenyl)-2-(methylamino)propan-1-one) – 23 October 2013, Hungary. 
59. 25B-N(BOMe)2 (2-(4-bromo-2,5-dimethoxyphenyl)-N,N-bis(2-methoxybenzyl)ethanamine) – 23 
October 2013, Hungary. 
60. Diphenhydramine (2-(diphenylmethoxy)-N,N-dimethylethanamine) – 23 October 2013, United 
Kingdom. 
61. Atomoxetine ((3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine) – 24 October 
2013, Denmark. 
62. Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)-4-piperidinyl]acetamide) – 24 
October 2013, Netherlands. 
63. 6-EAPB (1-(benzofuran-6-yl)-N-ethylpropan-2-amine) – 28 October 2013, Netherlands. 
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 64. AM-6527 5-fluoropentyl derivative (1-(5-fluoropentyl)-N-(napthalen-2-yl)-1H-indole-3-
carboxamide) – 7 November 2013, Germany. 
65. 4-MMA (N-methyl-1-(4-methylphenyl)propan-2-amine) – 13 November 2013, Poland. 
66. AM-2201 indazole analogue ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) – 
15 November 2013, Sweden. 
67. N-methyl-2-aminoindane (N-methylindan-2-amine) – 20 November 2013, Denmark. 
68. Embutramide (N-[2-ethyl-2-(3-methoxyphenyl)butyl]-4-hydroxy-butanamide) – 26 November 
2013, Bulgaria. 
69. ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
carboxamide) – 28 November 2013, Turkey and Germany. 
70. ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) 
– 3 December 2013, United Kingdom. 
71. βk-2C-B (2-amino-1-(4-bromo-2,5-dimethoxyphenyl)ethan-1-one) – 3 December 2013, United 
Kingdom. 
73. Butorphanol (17-cyclobutylmethyl-morphinan-3,14-diol) – 3 December 2013, Denmark. 
74. MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine) – 5 December 2013, Sweden. 
74. Lysergic acid 2,4-dimethylazetidide ('LSZ') ([(2S,4S)-2,4-dimethylazetidin-1-yl]-[(9R)-7-methyl-
6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-yl]methanone) – 10 December 2013, Slovenia. 
75. N,N-diethyl-2-(1-pentyl-1H-indol-3-yl)-4-thiazole-methanamine – 18 December 2013, Germany. 
76. N-(2-methoxyethyl)-N-(1-methylethyl)-2-(1-pentyl-1H-indol-3-yl)-4-thiazole-methanamine – 18 
December 2013, Germany. 
77. 1-(Cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1H-benzimidazole-5-carboxamide 
– 18 December 2013, Germany. 
78. A-796,260 isomer, ((E)-3,4,4-trimethyl-1-[1-(2-morpholinoethyl)indol-3-yl]pent-2-en-1-one) – 18 
December 2013, Germany. 
79. SDB-006 (N-benzyl-1-pentyl-1H-indole-3-carboxamide) – 19 December 2013, Finland. 
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 80. 5F-SDB-006 (N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide) – 19 December 2013, 
Finland. 
81. FUB-PB-22 (8-quinolyl 1-[(4-fluorophenyl)methyl]-3H-indole-3-carboxylate) – 19 December 
2013, Sweden. 
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